TD Asset Management’s Beam Therapeutics BEAM Stock Holding History

TD Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.7M	Sell	137,038 -38,986	-22%	-$1.18M	﹤0.01%	816
2026 Q1	$4.19M	Sell	176,024 -15,224	-8%	-$422K	﹤0.01%	823
2025 Q4	$5.3M	Buy	191,248 +46,068	+32%	+$1.18M	﹤0.01%	792
2025 Q3	$3.52M	Sell	145,180 -10,200	-7%	-$203K	﹤0.01%	853
2025 Q2	$2.64M	Sell	155,380 -56,400	-27%	-$982K	﹤0.01%	875
2025 Q1	$4.14M	Buy	211,780 +27,474	+15%	+$720K	﹤0.01%	812
2024 Q4	$4.57M	Hold	184,306	–	–	﹤0.01%	813
2024 Q3	$4.62M	Buy	184,306 +8,414	+5%	+$217K	﹤0.01%	821
2024 Q2	$4.12M	Buy	175,892 +13,200	+8%	+$324K	﹤0.01%	805
2024 Q1	$5.38M	Buy	+162,692	New	+$5.07M	0.01%	762
2020 Q3	–	Sell	-7,176	Closed	-$201K	–	1357
2020 Q2	$201K	Buy	+7,176	New	+$155K	﹤0.01%	1294

Other funds holding BEAM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CGH

Contrarius Group Holdings Hamilton, Bermuda $2.17B AUM 134.87% 1-Year Est. Return

TD Asset Management's BEAM Position: Q2 2026 in Review

TD Asset Management reduced its Beam Therapeutics (BEAM) stake by 22% in Q2 2026, selling an estimated $1.18M and leaving 137,038 shares worth $4.7M. The position accounts for ﹤0.01% of the portfolio, ranked #816.

TD Asset Management first reported a position in BEAM in Q2 2020 and has held it in 11 quarters since. The position peaked at $5.38M in Q1 2024. 195 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

TD Asset Management held 137,038 shares of Beam Therapeutics worth $4.7M as of Q2 2026.
TD Asset Management sold 38,986 Beam Therapeutics shares in Q2 2026, an estimated $1.18M.
Beam Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #816 holding.
TD Asset Management first reported a position in Beam Therapeutics in Q2 2020 and has held it in 11 quarters since.
TD Asset Management's Beam Therapeutics position peaked at $5.38M in Q1 2024.
195 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.